AIM: To determine the prevalence and significance of primary biliary cirrhosis (PBC)-specific autoantibodies in first-degree relatives (FDRs) of Greek PBC patients. METHODS: The presence of antimitochondrial antibodies (AMA) and PBC-specific antinuclear antibodies (ANA) were determined using indirect immunofluorescence assays, dot-blot assays, and molecularly based enzyme-linked immunosorbent assays in 101 asymptomatic for liver-related symptoms FDRs of 44 PBC patients. In order to specify our results, the same investigation was performed in 40 healthy controls and in a disease control group consisting of 40 asymptomatic for liver-related symptoms FDRs of patients with other autoimmune liver diseases namely, autoimmune hepatitis-1 or primary sclerosing cholangitis (AIH-1/PSC). RESULTS: AMA positivity was observed in 19 (only 4 with abnormal liver function tests) FDRs of PBC patients and none of the healthy controls. The prevalence of AMA was significantly higher in FDRs of PBC patients than in AIH-1/PSC FDRs and healthy controls [18.8%, 95% confidence interval (CI): 12%-28.1% vs 2.5%, 95% CI: 0.1%-14.7%, P = 0.01; 18.8%, 95% CI: 12%-28.1% vs 0%, 95% CI: 0%-10.9%, P = 0.003, respectively]. PBC-specific ANA positivity was observed in only one FDR from a PSC patient. Multivariate analysis showed that having a proband with PBC independently associated with AMA positivity (odds ratio: 11.24, 95% CI: 1.27-25.34, P = 0.03) whereas among the investigated comorbidities and risk factors, a positive past history for urinary tract infections (UTI) was also independently associated with AMA detection in FDRs of PBC patients (odds ratio: 3.92, 95% CI: 1.25-12.35, P = 0.02). CONCLUSION: In FDRs of Greek PBC patients, AMA prevalence is significantly increased and independently associated with past UTI. PBC-specific ANA were not detected in anyone of PBC FDRs.
AIM: To determine the prevalence and significance of primary biliary cirrhosis (PBC)-specific autoantibodies in first-degree relatives (FDRs) of Greek PBC patients. METHODS: The presence of antimitochondrial antibodies (AMA) and PBC-specific antinuclear antibodies (ANA) were determined using indirect immunofluorescence assays, dot-blot assays, and molecularly based enzyme-linked immunosorbent assays in 101 asymptomatic for liver-related symptoms FDRs of 44 PBC patients. In order to specify our results, the same investigation was performed in 40 healthy controls and in a disease control group consisting of 40 asymptomatic for liver-related symptoms FDRs of patients with other autoimmune liver diseases namely, autoimmune hepatitis-1 or primary sclerosing cholangitis (AIH-1/PSC). RESULTS: AMA positivity was observed in 19 (only 4 with abnormal liver function tests) FDRs of PBC patients and none of the healthy controls. The prevalence of AMA was significantly higher in FDRs of PBC patients than in AIH-1/PSC FDRs and healthy controls [18.8%, 95% confidence interval (CI): 12%-28.1% vs 2.5%, 95% CI: 0.1%-14.7%, P = 0.01; 18.8%, 95% CI: 12%-28.1% vs 0%, 95% CI: 0%-10.9%, P = 0.003, respectively]. PBC-specific ANA positivity was observed in only one FDR from a PSC patient. Multivariate analysis showed that having a proband with PBC independently associated with AMA positivity (odds ratio: 11.24, 95% CI: 1.27-25.34, P = 0.03) whereas among the investigated comorbidities and risk factors, a positive past history for urinary tract infections (UTI) was also independently associated with AMA detection in FDRs of PBC patients (odds ratio: 3.92, 95% CI: 1.25-12.35, P = 0.02). CONCLUSION: In FDRs of Greek PBC patients, AMA prevalence is significantly increased and independently associated with past UTI. PBC-specific ANA were not detected in anyone of PBC FDRs.
Authors: E I Rigopoulou; E T Davies; A Pares; K Zachou; C Liaskos; D-P Bogdanos; J Rodes; G N Dalekos; D Vergani Journal: Gut Date: 2005-04 Impact factor: 23.059
Authors: M Eric Gershwin; Carlo Selmi; Howard J Worman; Ellen B Gold; Mitchell Watnik; Jessica Utts; Keith D Lindor; Marshall M Kaplan; John M Vierling Journal: Hepatology Date: 2005-11 Impact factor: 17.425
Authors: W R Kim; K D Lindor; G R Locke; T M Therneau; H A Homburger; K P Batts; B P Yawn; J L Petz; L J Melton; E R Dickson Journal: Gastroenterology Date: 2000-12 Impact factor: 22.682
Authors: J M Turchany; R Uibo; T Kivik; J Van de Water; T Prindiville; R L Coppel; M E Gershwin Journal: Am J Gastroenterol Date: 1997-01 Impact factor: 10.864
Authors: Alessandro Granito; Wei-Hong Yang; Luigi Muratori; Mark J Lim; Ayako Nakajima; Silvia Ferri; Georgios Pappas; Chiara Quarneti; Francesco B Bianchi; Donald B Bloch; Paolo Muratori Journal: Am J Gastroenterol Date: 2009-10-27 Impact factor: 10.864
Authors: Stella Gabeta; Gary L Norman; Christos Liaskos; Panagiotis A Papamichalis; Theodoros Zografos; Athanasios Garagounis; Eirini I Rigopoulou; George N Dalekos Journal: J Clin Immunol Date: 2007-05-21 Impact factor: 8.542
Authors: Saeam Shin; In Ho Moh; Young Sik Woo; Sung Won Jung; Jin Bae Kim; Ji Won Park; Ki Tae Suk; Hyoung Su Kim; Mineui Hong; Sang Hoon Park; Myung Seok Lee Journal: World J Gastroenterol Date: 2017-10-21 Impact factor: 5.742
Authors: Panagiotis A Papamichalis; Kalliopi Zachou; Roidoula A Papamichali; Maria Ioannou; Nikolaos K Gatselis; George N Dalekos; George K Koukoulis Journal: J Transl Int Med Date: 2021-03-31